

Code (Nonproprietary name)	Indication	Status (Japan)	Remarks
<b>JR-141</b> BBB-Penetrating Iduronate-2-sulfatase (rDNA origin)	Hunter syndrome (LSD)	Phase III (Phase II in Brazil)	•ERT •J-Brain Cargo®
<b>JR-162</b> J-Brain Cargo® applied acid alpha-glucosidase (rDNA origin)	Pompe disease (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
<b>JR-171</b> BBB-Penetrating acid alpha-L Iduronidase (rDNA origin)	Hurler syndrome (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
<b>JR-441</b> BBB-Penetrating heparan N-sulfatase	Sanfilippo syndrome type A (LSD)	Preclinical	•ERT •J-Brain Cargo® •J-MIG System®
<b>JR-131</b> Darbepoetin Alfa (rDNA origin)	Renal anemia	Filed	•Co-developed with Kissei Pharmaceutical Co., Ltd. •Biosimilar
<b>JR-401X</b> Somatotropin (rDNA origin)	SHOX deficiency	Phase III	Expanded Indication of GROWJECT®
<b>JR-142</b> Long-acting growth hormone (rDNA origin)	Growth disorders	Preclinical	•J-MIG System®
<b>JR-041</b> Follicle stimulating hormone (rDNA origin)	Infertility	Phase I/II	Out-licensed to ASKA Pharmaceutical Co., Ltd.
<b>JR-031</b> Mesenchymal stem cells	Epidermolysis bullosa	Application for marketing approval in preparation	Expanded Indication of TEMCELL® HS Inj.
<b>JTR-161/JR-161</b> Dental pulp stem cells	Acute cerebral infarction	Phase I/II	•Co-developed with Teijin Limited